Generic name | treprostinil sodium |
Strength |
1 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL |
Form | vial |
Special Authority criteria |
Approval period |
---|---|
As monotherapy, for the treatment of World Health Organization (WHO)/New York Heart Association (NYHA) functional class IV pulmonary arterial hypertension (PAH), in patients who have had an inadequate response and/or a contraindication to the non-prostanoid therapies AND are not candidates for epoprostenol |
1 year |